ArticleMicrobiology spectrum2025
Accelerating extrapulmonary tuberculosis diagnosis with a rapid molecular assay.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Etiologic diagnosis of suspected tuberculous meningitis by multiplex PCR of cerebrospinal fluid.Journal of clinical microbiology · 2026Article
- Point-of-care core needle biopsy pathway for early diagnosis of lymph node masses: comparative costing of a scalable pathway.Health economics review · 2026Article
- Acute Pyogenic Ankle Monoarthritis Due to Tuberculosis: A Real-Life Clinical Conundrum.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrapulmonary tuberculosis (EPTB) is characterized by a very low bacterial load and could remain undiagnosed for a long time in a number of cases due to atypical presentation. Conventional methods and their time to results are not always helpful in rapidly making an EPTB diagnosis and initiating appropriate treatment. In order to accelerate the bacteriological confirmation, we evaluated the benefits of systematically using nucleic acid amplification test (NAAT) on extrapulmonary specimens for TB diagnosis in a developed country. From November 2017 to March 2021, all extrapulmonary samples received at the mycobacteriology department were subjected to both conventional methods and Xpert MTB/RIF Ultra. The time savings and the diagnostic performance of reflex tests were evaluated. During the study period, 691 samples were included, 85 (12.3%) were NAAT positive for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.